Pancreatic Cancer Research

ResearcherUniversity of VeronaNo recent work listed

Raffaella Casolino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4151-9736; OpenAlex author ID A5073756649. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers

Papers 13

  1. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Last author DOI 10.1016/j.esmoop.2023.100881↗
  2. Treatment of pancreatic cancer in 2022. Co-author DOI 10.1017/pcm.2023.2↗
  3. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. First author DOI 10.1177/17588359231189127↗
  4. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  5. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(22)00448-x↗
  6. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Co-author DOI 10.3390/cancers14133239↗
  7. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  8. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  9. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  10. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. First author DOI 10.3390/jcm10010149↗
  11. The emotional impact of surveillance programs for pancreatic cancer on high-risk individuals: A prospective analysis. Co-author DOI 10.1002/pon.5370↗
  12. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.0979↗
  13. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1322242↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Victor Biankin · 10 shared papers, 2021–2023 · strength 1.69
  2. Salvatore Paiella · 6 shared papers, 2018–2023 · strength 0.73
  3. Claudio Bassi · 7 shared papers, 2017–2023 · strength 0.73
  4. David Kuang-Fu Chang · 5 shared papers, 2021–2022 · strength 0.60
  5. Michèle Milella · 5 shared papers, 2021–2022 · strength 0.60
  6. Talia Golan · 4 shared papers, 2021–2023 · strength 0.59
  7. Aldo Scarpa · 5 shared papers, 2017–2022 · strength 0.53
  8. Giuseppe Malleo · 4 shared papers, 2017–2023 · strength 0.45
  9. Fieke E. M. Froeling · 3 shared papers, 2021 · strength 0.40
  10. Roberto Salvia · 3 shared papers, 2020–2023 · strength 0.38
  11. Antonio Pea · 3 shared papers, 2021 · strength 0.38
  12. Vincenzo Corbo · 3 shared papers, 2021–2022 · strength 0.37
  13. Chiara Braconi · 3 shared papers, 2021 · strength 0.33
  14. Darío Gregori · 2 shared papers, 2021–2023 · strength 0.27
  15. Amber L. Johns · 2 shared papers, 2022 · strength 0.27
  16. Rita Teresa Lawlor · 2 shared papers, 2022 · strength 0.27
  17. Claudio Luchini · 2 shared papers, 2022 · strength 0.27
  18. Douglas L. Riegert‐Johnson · 1 shared paper, 2023 · strength 0.20
  19. Michael J. Hall · 1 shared paper, 2023 · strength 0.20
  20. Pascal R. Hammel · 1 shared paper, 2023 · strength 0.20
  21. Chang‐Il Hwang · 1 shared paper, 2022 · strength 0.16
  22. Diane M. Simeone · 1 shared paper, 2023 · strength 0.16
  23. Geny Piro · 2 shared papers, 2017–2021 · strength 0.16
  24. Carmine Carbone · 2 shared papers, 2017–2021 · strength 0.16
  25. Stephan B. Dreyer · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.